Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy

Udenafil is a selective phosphodiesterase type 5 inhibitor made available in recent years for the treatment of erectile dysfunction. Herein, we evaluated independent predictors of potency recovery in radical prostatectomy (RP) patients who underwent penile rehabilitation with udenafil 50 mg. One hun...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of impotence research 2016-01, Vol.28 (1), p.25-30
Hauptverfasser:	Kim, T-H, Ha, Y-S, Choi, S H, Yoo, E S, Kim, B W, Yun, S-J, Kim, W-J, Kwon, Y S, Kwon, T G
Format:	Artikel
Sprache:	eng
Schlagworte:	59/57 692/499 692/699/2768/1575 Aged Biopsy Care and treatment Complications and side effects Drug therapy Enzyme inhibitors Erectile dysfunction Erectile Dysfunction - drug therapy Erectile Dysfunction - etiology Erectile Dysfunction - physiopathology Erectile Dysfunction - rehabilitation Health aspects Humans Impotence Male Medicine Medicine & Public Health Middle Aged original-article Patients Penis Pharmaceutical industry Phosphodiesterase 5 Inhibitors - administration & dosage Postoperative Complications - drug therapy Postoperative Complications - physiopathology Postoperative Complications - rehabilitation Prognosis Prostate cancer Prostatectomy Prostatectomy - adverse effects Prostatectomy - methods Prostatic Neoplasms - surgery Pyrimidines - administration & dosage Recovery of Function - drug effects Recovery of Function - physiology Rehabilitation Reproductive Medicine Republic of Korea Review boards Risk Factors rology Sexual disorders Sulfonamides - administration & dosage Surgery Treatment Outcome Urological surgery Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Udenafil is a selective phosphodiesterase type 5 inhibitor made available in recent years for the treatment of erectile dysfunction. Herein, we evaluated independent predictors of potency recovery in radical prostatectomy (RP) patients who underwent penile rehabilitation with udenafil 50 mg. One hundred and forty-three men who underwent RP were enrolled in a penile rehabilitation program using udenafil 50 mg every other day. The rate of regained potency in the study group was significantly higher compared with the recovery rate seen in patients who were not part of the penile rehabilitation program (41.3% vs 13.0%; P
ISSN:	0955-9930 1476-5489
DOI:	10.1038/ijir.2015.28